To our knowledge, there is a dearth of research regarding serum CXCR2 and CXCR4 concentrations in PC patients in relation to the clinicopathological characteristics of the tumor as well as the diagnostic and prognostic potential of these protein in comparison to the classical tumor biomarker (CEA) and the marker of inflammation (CRP). This evidence concerns the gene CXCR4 and pachyonychia congenita.